ALTO NEUROSCIENCE INC (ANRO)

Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights

ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm

Alto Neuroscience to Participate in Upcoming Investor Conferences

ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm

/PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alto Neuroscience, Inc....

ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm

Alto Neuroscience Enters Oversold Territory (ANRO)

ANRO Investors Have Opportunity to Join Alto Neuroscience, Inc. Fraud Investigation with the Schall Law Firm

Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder

Alto Neuroscience Announces Peer-Reviewed Publication in the Journal of Clinical Psychiatry Demonstrating Baseline Cognitive Performance is Not a Moderator of Response to Standard-of-Care Antidepressants

Alto Neuroscience to Participate in Upcoming Investor Conferences

ANRO Stock Earnings: Alto Neuroscience Beats EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Alto Neuroscience (NYSE:ANRO) just reported results for the second quarter of 2...

ANRO Stock Earnings: Alto Neuroscience Beats EPS for Q2 2024

ANRO stock results show that Alto Neuroscience beat analyst estimates for earnings per share the second quarter of 2024.

Alto Neuroscience Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Oversold Conditions For Alto Neuroscience (ANRO)

Alto Neuroscience Receives Funding Award from Wellcome Trust to Accelerate Development of ALTO-100 in Bipolar Depression Leveraging Precision Psychiatry Approach

Alto Neuroscience Announces Enrollment Completion in Phase 2b Study of ALTO-100 in Major Depressive Disorder

Friday 7/12 Insider Buying Report: ANRO, AHH

Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia

Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award Winner

Wake Up! 3 Lesser-Known Stocks Investors Are Sleeping On

Under-the-radar stocks offer incredible chances at massive returns with these shares representing compelling choices for investors.

Alto Neuroscience to Present at the Jefferies Global Healthcare Conference

Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer

ANRO Stock Earnings: Alto Neuroscience Misses EPS for Q1 2024

ANRO stock results show that Alto Neuroscience missed analyst estimates for earnings per share the first quarter of 2024.

ANRO Stock Earnings: Alto Neuroscience Misses EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Alto Neuroscience (NYSE:ANRO) just reported results for the first quarter of 20...

Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights

Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences

Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia

Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder

Tuesday 4/2 Insider Buying Report: WLKP, ANRO

Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights

Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors